Journal of Clinical Oncology, Vol 16, 527-535, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group

FM Uckun, MG Sensel, HN Sather, PS Gaynon, DC Arthur, BJ Lange, PG Steinherz, P Kraft, R Hutchinson, JB Nachman, GH Reaman and NA Heerema
Children's Cancer Group ALL Biology Reference Laboratory and Wayne Hughes Institute, St. Paul, MN 55113, USA. faitih-uckun@mercury.lh.org

PURPOSE: The nonrandom translocation t(1;19) has been associated with poor outcome in pediatric B-lineage acute lymphoblastic leukemia (ALL). Because most patients treated by contemporary therapies now achieve improved outcomes, we have reassessed the prognostic significance of t(1;19). PATIENTS AND METHODS: Cytogenetic data were accepted for 1,322 children (<21 years old) with newly diagnosed ALL enrolled between 1988 and 1994 on risk-adjusted studies of the Children's Cancer Group (CCG). Forty-seven patients (3.6%) were t(1;19) positive (+); 1,275 (96.4%) were t(1;19) negative (-). Clinical characteristics and treatment outcome were compared using standard methods. RESULTS: Translocation (1;19)+ patients were more likely than t(1;19)- patients to be 10 years of age or greater (P < .001) or CD10+ CD19+ CD34- (P < .0001), or nonwhite (P = .02). Patients with a balanced t(1;19) were less likely to be hyperdiploid than patients with an unbalanced der(19)t(1;19). Event-free survival (EFS) was similar for the overall group of t(1;19)+ and t(1;19)- patients, with 4-year estimates of 69.5% (SD, 6.8%) and 74.8% (SD, 1.3%; P = .48), respectively. However, patients with unbalanced der(19)t(1;19) had significantly better outcomes than patients with balanced t(1;19): 4-year EFS were 80.6% (SD, 7.1%) and 41.7% (SD, 13.5%), respectively (P = .003). These differences were maintained within the individual studies analyses and after exclusion of t(1;19)+ patients whose cells were hyperdiploid with more than 50 chromosomes. CONCLUSION: The overall group of t(1;19)+ patients, as well as the subgroup with an unbalanced der(19)+ (1;19) had outcomes similar to that of t(1;19)- patients, whereas patients with balanced t(1;19) had poorer outcomes. Thus, although the overall prognostic significance of t(1;19) has been obviated by contemporary risk-adjusted protocols, the balanced t(1;19) translocation remains an adverse prognostic factor.

This article has been cited by other articles:

				L. Kager, T. Lion, A. Attarbaschi, M. Koenig, S. Strehl, O. A. Haas, M. N. Dworzak, M. Schrappe, H. Gadner, G. Mann, et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children Haematologica, November 1, 2007; 92(11): 1561 - 1564. [Abstract] [Full Text] [PDF]

				K. R. Schultz, D. J. Pullen, H. N. Sather, J. J. Shuster, M. Devidas, M. J. Borowitz, A. J. Carroll, N. A. Heerema, J. E. Rubnitz, M. L. Loh, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Blood, February 1, 2007; 109(3): 926 - 935. [Abstract] [Full Text] [PDF]

				A. Andersson, T. Olofsson, D. Lindgren, B. Nilsson, C. Ritz, P. Eden, C. Lassen, J. Rade, M. Fontes, H. Morse, et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations PNAS, December 27, 2005; 102(52): 19069 - 19074. [Abstract] [Full Text] [PDF]

				W. L. Carroll Race and Outcome in Childhood Acute Lymphoblastic Leukemia JAMA, October 15, 2003; 290(15): 2061 - 2063. [Full Text] [PDF]

				W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF]

				A. K. Siraj, U. Ozbek, S. Sazawal, S. Sirma, G. Timson, A. Al-Nasser, M. Bhargava, H. El Solh, K. Bhatia, and M. I. Gutierrez Preclinical Validation of a Monochrome Real-Time Multiplex Assay for Translocations in Childhood Acute Lymphoblastic Leukemia Clin. Cancer Res., December 1, 2002; 8(12): 3832 - 3840. [Abstract] [Full Text] [PDF]

				S. Bhatia, H. N. Sather, N. A. Heerema, M. E. Trigg, P. S. Gaynon, and L. L. Robison Racial and ethnic differences in survival of children with acute lymphoblastic leukemia Blood, August 28, 2002; 100(6): 1957 - 1964. [Abstract] [Full Text] [PDF]

				J. M. Kim, J. Fang, S. Rheingold, R. Aplenc, R. Wasserman, and S. A. Grupp Cytoplasmic {micro} Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia Cancer Res., August 1, 2002; 62(15): 4212 - 4216. [Abstract] [Full Text] [PDF]

				D. L. Robinson Childhood Leukemia: Understanding the Significance of Chromosomal Abnormalities Journal of Pediatric Oncology Nursing, May 1, 2001; 18(3): 111 - 123. [Abstract] [PDF]

				A. M. Friedmann and H. J. Weinstein The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia Oncologist, August 1, 2000; 5(4): 321 - 328. [Abstract] [Full Text]

				F. M. Uckun, Y. Messinger, C.-L. Chen, K. O'Neill, D. E. Myers, F. Goldman, C. Hurvitz, J. T. Casper, and A. Levine Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor Clin. Cancer Res., December 1, 1999; 5(12): 3906 - 3913. [Abstract] [Full Text] [PDF]

				D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]